Compass Therapeutics
CMPX
125 hedge funds and large institutions have $529M invested in Compass Therapeutics in 2025 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 43 increasing their positions, 31 reducing their positions, and 10 closing their positions.
27,592% more call options, than puts
Call options by funds: $3.6M | Put options by funds: $13K
230% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 10
88% more capital invested
Capital invested by funds: $281M → $529M (+$247M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
39% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 31
30.95% more ownership
Funds ownership: 78.28% → 109.23% (+31%)
21% more funds holding
Funds holding: 103 → 125 (+22)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$22M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$15M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$11.1M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$10.5M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$8.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$1.8M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.73M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.54M |
| 4 |
SG Americas Securities
New York
|
-$706K |
| 5 |
Blackstone Inc
New York
|
-$584K |
CMPX Hedge Fund Activity: Q3 2025 in Review
125 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q3 2025, worth a combined $529M — up 88% from $281M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new CMPX positions and 10 closed out — a net gain of 23 holders — while 43 added to existing stakes and 31 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $22M. The largest seller was Caption Management, cutting an estimated $1.8M.
- 125 institutional investors held Compass Therapeutics (CMPX) as of Q3 2025, up from 103 in Q2 2025.
- Funds reported $529M of Compass Therapeutics stock for Q3 2025, up 88% quarter-over-quarter.
- 33 funds opened new Compass Therapeutics positions in Q3 2025 and 10 closed out, a net change of +23 holders.
- The largest Compass Therapeutics buyer in Q3 2025 was Suvretta Capital Management, an estimated $22M added.
- The largest Compass Therapeutics seller in Q3 2025 was Caption Management, an estimated $1.8M sold.
Based on aggregated 13F filings for Q3 2025.